In the realm of infectious diseases, Tuberculosis (TB) remains a formidable adversary. Despite the availability of effective treatment, the diagnosis of TB continues to pose significant challenges. This article aims to explore the latest diagnostic approaches employed in modern healthcare for TB.
The conventional diagnostic approach of TB predominantly relies on sputum smear microscopy and culture methods. These methods, while effective, have limitations in terms of sensitivity and speed. In resource-limited settings, these challenges are further compounded by the lack of sophisticated laboratory facilities.
In recent years, molecular diagnostic techniques have emerged as a promising alternative. The World Health Organization (WHO) endorses the GeneXpert MTB/RIF assay, a rapid molecular test that can detect TB and resistance to rifampicin within two hours. This technique, however, requires substantial financial investment and technical expertise.
Immunological tests, such as the Interferon Gamma Release Assays (IGRAs), are another contemporary diagnostic approach. These tests measure the immune response to TB proteins in blood. However, they cannot distinguish between latent TB infection and active TB disease, limiting their utility in certain clinical scenarios.
Advancements in imaging techniques have also contributed to improved TB diagnosis. High-resolution computed tomography (HRCT) and positron emission tomography (PET) can provide valuable information about the extent and activity of the disease. However, these techniques are not universally available and are often reserved for complex cases.
The landscape of TB diagnosis is evolving, with newer techniques offering improved accuracy and speed. However, these advancements come with their own set of challenges, including cost and accessibility. Therefore, a combination of traditional and contemporary diagnostic approaches, tailored to the local resources and epidemiology, is likely to yield the best results in the fight against TB.
1.
Year in Review: Non-Small Cell Lung Cancer
2.
Study suggests around 40% of postmenopausal hormone positive breast cancers are linked to excess body fat
3.
The need for more Latinx participants in Alzheimer's trials is urgent.
4.
Why palliative care goes hand in hand with treatment for people with cancer: Q&A
5.
MRD-Guided Azacitidine May Delay Relapse in AML, MDS
1.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
2.
The Danger of Methemoglobinemia and How to Prevent It
3.
Deciphering FFR: A Comprehensive Guide to Understanding Its Meaning
4.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
5.
Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
Thromboprophylaxis In Medical Settings
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation